GB2571937B - Stable liquid suspension composition of fludrocortisone - Google Patents

Stable liquid suspension composition of fludrocortisone Download PDF

Info

Publication number
GB2571937B
GB2571937B GB1803893.5A GB201803893A GB2571937B GB 2571937 B GB2571937 B GB 2571937B GB 201803893 A GB201803893 A GB 201803893A GB 2571937 B GB2571937 B GB 2571937B
Authority
GB
United Kingdom
Prior art keywords
fludrocortisone
liquid suspension
stable liquid
suspension composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1803893.5A
Other versions
GB2571937A (en
GB201803893D0 (en
Inventor
Maganbhai Patel Sanjaykumar
Patel Kamlesh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syri Ltd
Original Assignee
Syri Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syri Ltd filed Critical Syri Ltd
Priority to GB1803893.5A priority Critical patent/GB2571937B/en
Publication of GB201803893D0 publication Critical patent/GB201803893D0/en
Priority to PCT/IB2019/051696 priority patent/WO2019175703A1/en
Priority to EP19713218.6A priority patent/EP3764989A1/en
Publication of GB2571937A publication Critical patent/GB2571937A/en
Application granted granted Critical
Publication of GB2571937B publication Critical patent/GB2571937B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
GB1803893.5A 2018-03-12 2018-03-12 Stable liquid suspension composition of fludrocortisone Expired - Fee Related GB2571937B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB1803893.5A GB2571937B (en) 2018-03-12 2018-03-12 Stable liquid suspension composition of fludrocortisone
PCT/IB2019/051696 WO2019175703A1 (en) 2018-03-12 2019-03-03 Stable liquid suspension composition of fludrocortisone
EP19713218.6A EP3764989A1 (en) 2018-03-12 2019-03-03 Stable liquid suspension composition of fludrocortisone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1803893.5A GB2571937B (en) 2018-03-12 2018-03-12 Stable liquid suspension composition of fludrocortisone

Publications (3)

Publication Number Publication Date
GB201803893D0 GB201803893D0 (en) 2018-04-25
GB2571937A GB2571937A (en) 2019-09-18
GB2571937B true GB2571937B (en) 2021-07-14

Family

ID=61972944

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1803893.5A Expired - Fee Related GB2571937B (en) 2018-03-12 2018-03-12 Stable liquid suspension composition of fludrocortisone

Country Status (3)

Country Link
EP (1) EP3764989A1 (en)
GB (1) GB2571937B (en)
WO (1) WO2019175703A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE063183T2 (en) * 2020-02-25 2024-01-28 Labomed Pharmaceutical Company S A Oral solutions comprising fludrocortisone acetate
CN111803457A (en) * 2020-07-20 2020-10-23 华益药业科技(安徽)有限公司 Fludrocortisone acetate tablet and processing technology thereof
CN111759812A (en) * 2020-07-20 2020-10-13 华益药业科技(安徽)有限公司 Fludrocortisone acetate tablet for inhibiting proliferation of connective hoof tissue and processing technology thereof
CN111759814A (en) * 2020-07-20 2020-10-13 华益药业科技(安徽)有限公司 Fludrocortisone acetate tablet for resisting inflammation and processing technology
CN113350297B (en) * 2021-06-11 2022-11-04 河南金大众生物工程有限公司 Tilmicosin dry suspension and preparation method thereof
CA3227492A1 (en) * 2021-07-30 2023-02-02 Hahn-Jun Lee Clemizole formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
WO2003082243A1 (en) * 2002-04-03 2003-10-09 Venus Danilo R Oral suspension formulation
US20060093631A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060013858A1 (en) * 2002-10-29 2006-01-19 Trune Dennis R Fludrocortisone treatment for hearing loss
US8022054B2 (en) * 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
WO2010068775A2 (en) * 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CA2949480A1 (en) * 2014-02-24 2015-08-27 Urigen Pharmaceuticals, Inc. Compositions of pentosan polysulfate salts for oral administration and methods of use
US11207307B2 (en) * 2016-06-16 2021-12-28 Azurity Pharmaceuticals, Inc. Composition and method for proton pump inhibitor suspension

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
WO2003082243A1 (en) * 2002-04-03 2003-10-09 Venus Danilo R Oral suspension formulation
US20060093631A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
European Journal of Pharmaceutics and Biopharmaceutics, vol. 55, 2003, pages 209-213 *

Also Published As

Publication number Publication date
GB2571937A (en) 2019-09-18
EP3764989A1 (en) 2021-01-20
GB201803893D0 (en) 2018-04-25
WO2019175703A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
GB2571937B (en) Stable liquid suspension composition of fludrocortisone
ZA201802150B (en) Compounds useful as modulators of trpm8
HK1252623A1 (en) Heterocyclic compounds useful as modulators of tnf alpha
IL281492A (en) Modulators of pnpla3 expression
IL283967A (en) Modulators of hsd17b13 expression
GB201912802D0 (en) Characterisation of emulsion stability
IL269695A (en) Compounds useful as inhibitors of alcat 1
ZA202007537B (en) Modulators of apol1 expression
EP3927868C0 (en) Use of sulfidic compositions
IL290324A (en) Compositions of trofinetide
GB201718468D0 (en) Stable liquid pharmaceutical compositions of bortezomb
PL3449931T3 (en) Use of cerebrolysin
ZA202105399B (en) Use of spiropidion
IL285333A (en) Modulators of malat1 expression
GB201919180D0 (en) New composition of matter
IL273237A (en) Novel heterocyclic compounds as modulators of mglur7
SG11202105136WA (en) Application of chidamide
GB201913701D0 (en) Composition of matter
IL270891B (en) Formation of stable cartilage
SG11202010971XA (en) Small molecule modulators of mhc-i
PT3901141T (en) Novel form of isoquinolinesulfonamide
GB201910665D0 (en) Novel form of compounds
GB201910666D0 (en) Novel form of compounds
ZA202201719B (en) Stable polymorphic form of 6-fluoro-9-methyl-9h-beta-carboline and uses thereof
GB201809911D0 (en) Use of trpv1 agonists

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20220312